Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Our products and services are used to help care for critically and chronically ill patients.
Our product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, we focus on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.
Fresenius Kabi employs around 36,627 people worldwide, with in 2019 the company reported sales of more than €6,919 millions.
With our corporate philosophy of “caring for life”, we are committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.
1462The Hirsch Pharmacy is opened in Frankfurt am Main, Germany. The Fresenius family assumes ownership in the 19th century.
1912The pharmacist and proprietor of the Hirsch Pharmacy, Dr. Eduard Fresenius, founds the pharmaceutical company Dr. E. Fresenius. Its main products are pharmaceutical specialties such as injection solutions, serologic reagents and Bormelin nasal ointment.
1933/34The manufacturing company is separated from the Hirsch Pharmacy and moves to Bad Homburg. Dr. Fresenius devotes more and more time to the company, which grows to around 400 employees.
1966Fresenius starts to sell dialysis machines and dialyzers manufactured by various foreign companies and gains substantial market shares.
1974Fresenius starts to manufacture infusion solutions and medical disposables in St. Wendel, Saarland.
1979The first ready-to-use tube feed Fresubin® is introduced.
1984Establishment of the home care concept by which patients who have to be fed enterally (intake of nutrients involving the gastro-intestinal tract) can be cared for at home. At the same time expansion of the enteral nutrition range.
1988The within Fresenius developed Aminomix® Two-Chamber-Bag for parenteral nutrition is launched.
1999Effective January 1, Fresenius Kabi is formed by combining Fresenius Group’s Pharma division with the business acquired from Pharmacia & Upjohn (Kabi). The new company is Europe’s leader in the field of nutrition and infusion therapy, offering a comprehensive product and service portfolio worldwide for hospitals and patients at home.
2000Fresenius Kabi accelerates its worldwide business expansion by opening up new growth markets in Asia, Africa and Latin America.
2003The business segment Fresenius HemoCare is reallocated within the Fresenius Group. Due to their similar technology platform, the Infusion Technology and Transfusion Technology Divisions are combined under one management and assigned to Fresenius Kabi.
2004Fresenius Kabi strengthens its market positions with acquisitions in South Africa and Czech Republic as well as with a joint venture in Australia.
2005Expansion of I.V. drug portfolio via acquisition of the Portuguese pharmaceutical company Labesfal. Fresenius Kabi strengthens product portfolio and production network of medical devices through the acquisition of the business of Clinico.
2006Acquisition of Argentinean pharmaceutical company Filaxis: Expansion of I.V. drug portfolio.
2007Fresenius Kabi strengthens business activities through acquisitions. Blood volume replacement: Acquisition of blood volume replacement business of Japanese pharmaceutical company Kyorin I.V. Drugs: Acquisition of the Chilean company Laboratorio Sanderson and the Italian company Ribbon Clinical Nutrition: Acquisition of the enteral nutrition businesses from Nestlé in France and Spain.
2008Fresenius Kabi grows its I.V. generics business and expands into oncology drugs with the Dabur Pharma acquisition. Fresenius Kabi enters the North American pharmaceuticals market and becomes a globally leading supplier in the field of intravenously administered generic drugs via the acquisition of the U.S. based APP Pharmaceuticals.
2012Fresenius Kabi acquires the transfusion technology company Fenwal and creates a global leader in transfusion technology with a broad product portfolio for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems.
2014Fresenius Kabi has over 32,000 employees and markets more than 100 different product groups in over 160 countries and continues to expand its product range and global presence.
2016Fresenius Kabi expands its portfolio to ready-to-administer prefilled syringes by acquiring the U.S. BD Rx business from Becton Dickinson.
2017Fresenius Kabi enters the growing biosimilars sector by acquiring an R&D pipeline with a focus on autoimmune diseases and oncology.
2019Fresenius Kabi launches its first biosimilar in Europe.
Within clinical nutrition, Fresenius Kabi is one of the few companies worldwide to offer parenteral nutrition (administered intravenously) and enteral nutrition (administered as sip or tube feed via the gastrointestinal tract), as well as nutrition pumps and infusion disposables.